Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mproUK + alteplase
- Development stage
- Unknown
- Lead developer
- Thrombolytic Science International
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
mproUK + low-dose tPA is an intravenous dual thrombolytic regimen developed by Thrombolytic Science International (TSI) for the treatment of ischemic stroke and acute myocardial infarction. The therapy consists of a mutant form of pro-urokinase (mproUK, also known as HisproUK or M5) and a low dose of alteplase (tPA). This combination is designed to mimic the body's natural physiological fibrinolytic mechanism: a small dose of tPA initiates clot lysis by activating fibrin-associated plasminogen, which then creates a binding site for mproUK to complete the dissolution of the fibrin clot. This sequential action aims to provide more efficient and safer thrombolysis compared to standard-dose tPA monotherapy, specifically by reducing the risk of symptomatic intracranial hemorrhage and preserving plasma fibrinogen levels.
- Other names
- mproUK + low-dose tPAtPA/HisproUKmutant pro-urokinase + alteplase
02
Targets
Fibrin (Factor Ia)PLG (Plasminogen)
Beyond the preview
Go deeper on mproUK + alteplase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mproUK + alteplase.